Article Text

Download PDFPDF
Recurrent metastatic angiosarcoma presenting as Kasabach-Merritt syndrome
  1. Jeyhan Boman Dhabhar1 and
  2. Varshil Mehta2
  1. 1Medical Oncology, PD Hinduja National Hospital and Medical Research Centre, Mumbai, India
  2. 2Medicine, Northwick Park Hospital, Harrow, UK
  1. Correspondence to Dr Varshil Mehta; varshil91{at}


Angiosarcoma is an incredibly rare type of malignancy, accounting for only 1%–2% of all soft-tissue sarcomas globally. It is clinically, pathologically and radiologically difficult to diagnose angiosarcoma owing to its varied presentation with little or no well-defined imaging findings.

Kasabach-Merritt syndrome is also a lesser-heard entity which carries extremely poor prognosis. It is primarily seen in infants with vascular malformations and in kaposiform haemangioendothelioma. It is a condition of consumptive coagulopathy and only few of the cases have been reported so far in the adults with a background of angiosarcoma.

This report presents the case of a male in his 70s who was diagnosed with metastatic angiosarcoma and experienced a complicated disease course due to Kasabach-Merritt syndrome.

  • malignant disease and immunosuppression
  • screening (oncology)
  • head and neck cancer
  • prevention
  • skin cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @drvarshilmehta

  • Contributors JBD and VM both contributed equally towards the writing of the manuscript. JBD and VM share first coauthorship.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.